Incyte Completes Acquisition of Vega Therapeutics, Expanding its Hematology Portfolio

The following announcement is from a press release from Incyte. Read the full press release here.

Incyte announced July 6, 2026, it has completed its acquisition of Vega Therapeutics Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease to Incyte’s hematology portfolio.

“With the acquisition complete, VGA039 adds one of the most promising late-stage hematology assets in development to our portfolio. As a potential first-in-class therapy, VGA039 is a strong strategic fit with our hematology franchise and expands our presence into bleeding disorders,” said Bill Meury, Chief Executive Officer of Incyte. “Our priority is to advance the Phase 3 program, and we look forward to partnering with our talented new colleagues from Vega to progress VGA039 through clinical development.”